- Home
- AGIO vs ECVT Comparison
AGIO vs ECVT Comparison
Compare AGIO & ECVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGIO | ECVT |
|---|---|---|
| Founded | 2007 | 1935 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2013 | 2017 |
Fundamental Metrics
Financial Performance| Metric | AGIO | ECVT |
|---|---|---|
| Price | $31.82 | $12.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $38.88 | $14.00 |
| AVG Volume (30 Days) | 856.4K | ★ 1.7M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | $43,011,000.00 | ★ $723,515,000.00 |
| Revenue This Year | $76.75 | $29.07 |
| Revenue Next Year | $170.73 | $6.71 |
| P/E Ratio | ★ N/A | $327.25 |
| Revenue Growth | N/A | ★ 2.70 |
| 52 Week Low | $22.24 | $7.39 |
| 52 Week High | $46.00 | $15.09 |
Technical Indicators
Market Signals| Indicator | AGIO | ECVT |
|---|---|---|
| Relative Strength Index (RSI) | 62.62 | 43.04 |
| Support Level | $26.71 | $12.74 |
| Resistance Level | $36.07 | $15.01 |
| Average True Range (ATR) | 1.52 | 0.33 |
| MACD | 0.29 | -0.03 |
| Stochastic Oscillator | 97.47 | 34.04 |
Price Performance
Historical ComparisonAbout AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
About ECVT Ecovyst Inc.
Ecovyst Inc is an integrated and provider of materials, specialty catalysts and services. Its products contribute to lower emissions and cleaner air, higher fuel efficiency and cleaner fuels, and key enablers to advance transition to clean energy. The company has one operating segment. The Company's single reportable segment, Ecoservices, derives its revenue through the sale of virgin and regenerated sulfuric acid products and services.